Home|Journals|Articles by Year Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access

Review Article

J App Pharm Sci. 2014; 4(9): 114-119

Suggesting a new combination of antiviral agents: Targeting the Herpes Simplex Virus

Subathra Devi C., Taneesha Chawla, Nida Itrat Abbasi, Nupoor Neha Upadhyay, Mohanasrinivasan V..

Herpes simplex is a viral disease caused by herpes simplex virus type 1 and type 2.Several broad spectrum drugs are available but most of the strains developed resistance against it. To overcome this problem, we are suggesting a new combination drug for the treatment of herpes simplex. The main aim of the hypothesis is to formulate a topical drug and an intravenously administered drug against herpes simplex virus. Chebulagic acid and Punicalagin inhibit HSV-1 entry at non-cytotoxic doses in A549 human lung cells. Sodium is important to curb the proliferation and cell to cell spread of Herpes simplex virus. TA205, an antitalin monoclonal antibody can be microinjected in human fibroblasts. It causes allosteric inhibition on integrin binding to the talin protein FERM domain. Sodium lauryl sulphate is a surfactant which enhances intra epidermal drug delivery without increasing transdermal delivery. Amphipathic DNA polymers work against HIV binding and entry. Candidate topical microbicides are efficient against viral entry and cell to cell spread by binding HSV glycoprotein B. Thus, a combination of the above mentioned drugs can be used to prevent HSV binding, cell to cell spread and infection.

Key words: HSV,aciclovir, integrin, chebulagic acid, monoclonal antibody

Full-text options

Full-text Article

American Journal of Physiology, Biochemistry and Pharmacology


BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.